Original contribution

Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate or severe asthma

Eng Cern Gan, MBBS, MRCS (Edin), MMED (ORL), FAMS\(^a,b,\)*, Al-Rahim R. Habib, MSc\(^a\), Alykhan Rajwani, BSc\(^a\), Amin R. Javer, BSc, MD, FRCSC, FARS\(^a\)

\(^a\) Division of Otolaryngology, University of British Columbia, St. Paul’s Sinus Centre, 1081 Burrard St., Vancouver, British Columbia, Canada
\(^b\) Department of Otolaryngology–Head & Neck Surgery, Changi General Hospital, 2 Simei Street 3, Singapore

ARTICLE INFO

Purpose: 1. To assess the efficacy of omalizumab therapy in improving sinonasal outcomes in refractory allergic fungal rhinosinusitis (AFRS) patients with moderate or severe asthma. 2. To determine if omalizumab therapy reduces the usage of corticosteroids or antifungal therapy in AFRS patients

Method: Design: The clinical charts of patients with AFRS with moderate or severe asthma who received at least three subcutaneous injections of omalizumab therapy between 1st January 2012 and 1st May 2014 were retrospectively reviewed. These patients had undergone bilateral functional endoscopic sinus surgery (FESS) and failed adjunct medical treatments (oral or topical corticosteroids and/or antifungal therapy) prior to omalizumab therapy.

Results: Seven patients met the inclusion criteria and were included in this study. The mean age of the patients was 48.14. The average number of subcutaneous omalizumab injections was 7.57 (range 6–11) with a mean dosage of 287 mg (range 225–375 mg). The mean pre-omalizumab treatment Sino-Nasal Outcome Test-22 (SNOT-22) score was 52.14 while the mean post-omalizumab treatment SNOT-22 score was 35.86 (31% improvement). The mean pre-omalizumab therapy Phillpott–Javer endoscopic score (over the last one year before omalizumab therapy) was 36 while the mean post-omalizumab therapy endoscopic score (from the last clinic visit) was 14 (61% improvement). Omalizumab therapy reduced the dependence of AFRS patients on corticosteroid and antifungal treatments.

Conclusion: Omalizumab therapy can be considered as a potential adjunct for the treatment for patients with refractory AFRS with moderate or severe asthma. However, larger prospective studies to confirm the findings of this study will be required.

Crown Copyright © 2015 Published by Elsevier Inc. All rights reserved.

☆ Conflict of interests: None.

⁎ Corresponding author at: Department of Otolaryngology–Head & Neck Surgery, Changi General Hospital, 2 Simei Street 3, Singapore, 529889. Tel.: +65 6788 8833, +1 604 806 9926; fax: +65 6781 6435, +1 604 806 9690.

E-mail address: engcern@gmail.com (E.C. Gan).

http://dx.doi.org/10.1016/j.amjoto.2015.05.008
0196-0709/Crown Copyright © 2015 Published by Elsevier Inc. All rights reserved.

Please cite this article as: Gan EC, et al, Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate..., Am J Otolaryngol–Head and Neck Med and Surg (2015), http://dx.doi.org/10.1016/j.amjoto.2015.05.008
1. Introduction

Allergic fungal rhinosinusitis (AFRS) is a noninvasive form of fungal rhinosinusitis (FRS) [1]. It accounts for approximately 7% of all chronic sinusitis cases requiring surgery [2]. The hallmark of this disease is the presence of thick peanut butter-like allergic mucin in the sinuses with histological findings of degenerating eosinophils, Charcot-Leyden crystals and fungal hyphae without the evidence of sinonasal tissue invasion [2]. The typical AFRS patients are young, immunocompetent adults presenting with symptoms of CRS. The benchmark for the diagnosis of AFRS for many years has been the Bent and Kuhn criteria [3]. These include the presence of type I IgE-mediated hypersensitivity, nasal polyposis, characteristic CT findings (double density sign), eosinophilic or allergic mucin and a positive fungal smear [3].

Although AFRS has been recognized as an independent subset of CRS for over 30 years, the pathophysiology remains unknown and controversial. In a literature review by Ferguson et al., two popular theories were found [4]. The allergic (immunologic) theory proposed by Manning et al., was derived from the allergic bronchopulmonary aspergillosis (ABPA) model. They believed that an atopic host exposed to fungi resulted in antigenic stimulation by a combination of Gel and Coomb type I and type III hypersensitivity, leading to an intense inflammatory response [5,6]. The eosinophilic theory was suggested by Ponikou et al. when they demonstrated that eosinophilic chemotaxis in response to extramucosal fungi was the hallmark of the inflammatory reaction in AFRS [7]. The term eosinophilic mucin rhinosinusitis (EMRS) was then coined by Ferguson et al. to describe the non-allergic group of patients who have AFRS-like features in the absence of demonstrable fungal hyphae [4]. Dysregulation of immunologic controls of upper and lower airway eosinophilia was believed to be the underlying mechanism in EMRS.

The first step in the management of AFRS is complete and meticulous functional endoscopic sinus surgery (FESS) to debride and remove all polypoid disease, allergic mucin and fungal debris [2,8]. The aim of FESS is to restore ventilation, improve drainage of the paranasal sinuses and reduce the antigenic stimulus [9,10]. Following this, a combination of adjunct medical treatment is often required to keep the disease in a dormant state. These include topical and systemic corticosteroids and antifungal agents, immunotherapy and nasal rinses. Unfortunately, there is a subset of patients who are refractory to these treatments and the search for a salvage therapy continues.

Omalizumab is a humanized monoclonal anti-IgE antibody that has been shown to be an effective adjuvant therapy in severe atopic asthma, allergic rhinitis, CRS with nasal polyposis (CRSwNP) and asthma and ABPA [11–21]. Omalizumab decreases free IgE levels by binding to free circulating IgE. This process inhibits the binding of IgE to the high-affinity IgE receptors [22]. In addition, omalizumab reduces IgE receptors on mast cells, basophils and dendritic cells [23]. As an increase in local production of IgE is implicated in the pathophysiology of CRSwNP and AFRS [5,6] omalizumab may have a potential benefit in these patients.

Furthermore, given the pathophysiological similarity between ABPA and AFRS and recent case reports [14–18] and case series[19] demonstrating improvement in the clinical outcome of omalizumab in ABPA patients, the efficacy of omalizumab in patients with AFRS should be explored. Hence in this study, we aim to compare the sinonasal outcomes before and after omalizumab therapy in patients with refractory AFRS and moderate to severe asthma.

2. Methods

The clinical charts of AFRS patients with moderate or severe asthma who had undergone FESS and failed adjunct medical treatments (topical and systemic corticosteroid and oral itraconazole) between January 2012 and February 2013 were retrospectively reviewed at St Paul’s Sinus Centre in Vancouver, Canada. Patients who had received omalizumab during this period were selected for this study. The study received approval from the University of British Columbia Clinical Research Ethics Board. The regimen for medical treatments were as follows: a course of systemic steroid consisted of a tapering dose of oral prednisolone at 40 mg daily for 4 days, followed by 30 mg daily for 4 days, followed by 20 mg daily for 4 days and 10 or 5 mg daily for 1 month; topical steroid used was budesonide suspules (0.5 mg/ml × 2 ml) applied through the Mucosal Atomization Device (MAD) in the Mygind position (1 ml in each nostril); oral itraconazole dosage was 100 mg bid for at least 6 weeks duration. The following data were collected form the patients’ charts:

1. Patients’ demographics and baseline characteristics
2. Change in sinonasal symptoms before and after omalizumab therapy (as documented by the SNOT-22 score)
3. Change in endoscopic mucosal disease before and after omalizumab therapy (as documented by the Phillpott-Javer endoscopic staging for AFRS)
4. Change in the frequency and dosage of adjunct medical treatment postsurgery (oral and topical corticosteroids and antifungal agents) before and after omalizumab therapy
5. Documented side effects from omalizumab therapy.

The Philpott-Javer endoscopic staging system (Fig. 1) is a validated system that was derived from modifications made to the Kuperberg endoscopic staging system [24]. Each sinus cavity and the olfactory cleft are scored independently on a scale from 0 to 9 based on the degree of mucosal inflammation. An additional 1-point is allocated for each sinus if allergic mucin is noted grossly. This allows for a maximum score of 10 points per sinus cavity, 50 points for each side of the nose (including the olfactory cleft) and 100 points for the total maximum bilateral score. Such a system is much more sensitive and allows for much better tracking of disease control postoperatively.

2.1. Statistical analysis

Demographic and baseline characteristics were extracted from patient charts and recorded for each subject.
Demographic data included age (years), sex, history of smoking and race. Baseline characteristics included presence or absence of asthma, forced expiratory volume in one second (FEV₁), immunoglobulin-E level (IU/ml), SNOT-22 and endoscopic score (Philpott–Javer) immediately prior to receiving treatment and current medications. Dosage and frequency of omalizumab injections were dependant on each patient’s weight and IgE level. Subcutaneous dosage of omalizumab ranged from 150 to 375 mg and was offered in either 2 or 4-week intervals. Categorical, explanatory variables were summarized by frequency and absolute proportion. Continuous, explanatory variables were summarized by mean, standard deviation and range. The primary outcome variables were change in SNOT-22, endoscopic mucosal scores and IgE levels evaluated before and after treatment. As the duration of treatment varied among patients included in this case series, the endoscopic score was averaged over each respective follow-up period. The outcome variables were recorded as continuous, numerical outcomes and summarized by mean and standard deviation. The number of injections received and months treated with omalizumab were also reported. Frequency of concurrent medication was recorded and compared to baseline levels as categorical outcome variables. These observations were reported by count and absolute proportion.

Fig. 1 – The Philpott–Javer endoscopic staging system.
Results

A total of 8 patients received omalizumab, of which 1 patient (13%) did not continue treatment due to a significant reaction during initial administration. This patient had fever and dizziness immediately post injection. Symptoms resolved soon after, with no additional treatments or medication provided by the attending nursing staff. Omalizumab therapy was immediately discontinued and the symptoms did not recur. Excluding this patient from the review, this case series included 7 patients, consisting of 3 (43%) males and 4 (57%) females. The mean age of this cohort was 48.1 ± 11.8 years. All patients presented with moderate or severe asthma prior to receiving treatment of omalizumab, with a mean FEV1 of 2.7 ± 0.3 liters. Patients had undergone on average, 2 ± 1.5 sinus surgeries (range: 1–5) and 0.7 ± 0.8 (range: 0–2) office-based polypectomies prior to receiving treatment. Pre-omalizumab medications consisted of 7 (100%) patients self-administering topical budesonide, 3 (43%) received oral prednisone and 2 (29%) utilized oral itraconazole. Demographic data are summarized in Table 1.

Patients presented with a mean IgE-level of 238.1 ± 295.2 IU/ml (range: 19–882). An average of 12.3 ± 5.2 (range: 7–21) injections was administered, with mean follow-up time of 9.7 ± 2.9 (range: 7–14) months. The mean dose of omalizumab administered was 285.7 ± 57.5 mg (range: 200–375 mg). Among the study cohort, 5 (71%) patients receive injections every 4 weeks, whereas the remaining 2 (29%) patients receive injections at 2 week intervals.

The mean difference between pre and post SNOT-22 scores was 16.3 ± 17.1 (range: −1 to 47) points (31% improvement) (Fig. 2). Six of 7 (86%) of patients reported a reduction in sinus symptoms and subsequent improvement in quality of life post treatment. The mean difference in pre and post endoscopic scores was 22.0 ± 5.7 (range: 16–34 points), (61% improvement) (Fig. 3). The mean difference between pre and post IgE level was 60.9 ± 276.3 (range: −164 to 651 IU/mL) (Fig. 4). These observations were reported on average 7.9 ± 1.4 (range: 6–9) months post treatment. The use of concurrent medications was re-evaluated during the follow-up period. In regard to lung function, mean FEV1% predicted improved by 9.4 ± 1.2% (range: −6.6 to 14.9%, Fig. 5). Of all patients using budesonide prior to receiving omalizumab therapy (n = 7), 3 (43%) experienced a change in frequency and 1 (14%) discontinued use completely. Of those experiencing a change in frequency, 3 (75%) reduced their budesonide usage from twice daily to once daily. Of the three patients receiving oral prednisone prior omalizumab, all discontinued usage during the follow-up period. Similarly, the use of oral itraconazole was ceased in 1 of 2 (50%) patients after commencement of omalizumab injections. During this observational period, no patients were found to require subsequent office-based polypectomy or revision FESS after receiving omalizumab. The IgE levels post omalizumab therapy decreased significantly in two patients but were mostly slightly elevated in the remaining patients (Fig. 4).

Table 1 – Subject demographics and baseline characteristics.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Mean (SD)/frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>48.1 (11.8)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>3 (43%)</td>
</tr>
<tr>
<td>Females</td>
<td>5 (57%)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>5 (71%)</td>
</tr>
<tr>
<td>South Asian</td>
<td>2 (29%)</td>
</tr>
<tr>
<td>Forced expiratory volume (liters)</td>
<td>2.7 (0.3)</td>
</tr>
<tr>
<td>Number of sinus surgeries</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>2.0 (1.5)</td>
</tr>
<tr>
<td>Range</td>
<td>1–5</td>
</tr>
<tr>
<td>Number of office-based polypectomies</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>0.7 (0.8)</td>
</tr>
<tr>
<td>Range</td>
<td>0–2</td>
</tr>
<tr>
<td>Pre treatment immunoglobulin-E (IU/ml)</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>238.1 (295.2)</td>
</tr>
<tr>
<td>Range</td>
<td>19–882</td>
</tr>
</tbody>
</table>

Fig. 2 – Comparison of SNOT-22 scores pre and post omalizumab therapy.

Fig. 3 – Comparison of endoscopic scores pre and post omalizumab therapy.
and patients with first reported

Fig. 5

It has been reported that 70–88% of asthmatic patients experience sinonasal symptoms [25] and patients with CRSwNP are more likely to have concurrent asthma [26,27]. Although there are no available data in the literature on the prevalence of asthma in AFRS patients, most rhinologists would agree that a significant number of AFRS patients do suffer from asthma as well. Evans and Coop [28] first reported a positive effect of omalizumab on a patient with refractory AFRS in 2014. However, this study is believed to be the first reported case series in the English literature on the effects of omalizumab in post-FESS AFRS patients with moderate to severe asthma who have failed adjunct medical treatments. These medical treatments included topical (budesonide respules) and oral corticosteroids (prednisolone) and oral antifungal agent (itraconazole). Our study showed that patient symptom scores as well as endoscopic mucosal stage improved significantly after subcutaneous injections of omalizumab with a mean follow up period of 9.7 months.

Fig. 4 – Comparison of medication usage pre and post omalizumab therapy.

4. Discussion

It has been reported that 70–88% of asthmatic patients experience sinonasal symptoms [25] and patients with CRSwNP are more likely to have concurrent asthma [26,27]. Although there are no available data in the literature on the prevalence of asthma in AFRS patients, most rhinologists would agree that a significant number of AFRS patients do suffer from asthma as well. Evans and Coop [28] first reported a positive effect of omalizumab on a patient with refractory AFRS in 2014. However, this study is believed to be the first reported case series in the English literature on the effects of omalizumab in post-FESS AFRS patients with moderate to severe asthma who have failed adjunct medical treatments. These medical treatments included topical (budesonide respules) and oral corticosteroids (prednisolone) and oral antifungal agent (itraconazole). Our study showed that patient symptom scores as well as endoscopic mucosal stage improved significantly after subcutaneous injections of omalizumab with a mean follow up period of 9.7 months.

The clinical improvement seen in this study is in agreement with other studies demonstrating a favorable outcome in CRSwNP treated with omalizumab therapy [20,21]. In a small pilot study by Penn and Mikula among post FESS atopic asthma patients with CRSwNP treated with omalizumab, there was a significant reduction in the size of the polyps in the anti-IgE group compared to control [20]. In addition, they found that the severity of nasal polyposis correlated with total serum IgE levels in atopic asthmatics. In their study, omalizumab was administered by subcutaneous injection in 2- or 4-week intervals with a dose range of 150–375 mg (depending on patients’ weight and pretreatment IgE levels) for an average of 5.5 months (range 3–8 months). In the only randomized double-blind placebo-controlled trial on omalizumab therapy on nasal polyps and asthma patients, Gevaert et al. demonstrated that there was significant improvement in total nasal endoscopic polyp scores, CT findings, airway symptoms and quality of life scores after 16 weeks of omalizumab treatment [21]. These improvements were seen irrespective of the presence of allergy.

Apart from reduction in symptom and endoscopic mucosal scores, omalizumab injections in our study reduced patient dependence on oral prednisolone and oral itraconazole, both of which are associated with potential significant side effects. All our patients were weaned off oral prednisolone therapy after commencement of omalizumab therapy. In a study of 19 CRSwNP patients with severe asthma treated with omalizumab, Vennera et al. demonstrated that there was a significant reduction in patient dependence on intranasal steroids (95% pre-treatment vs 42% post-treatment) and avoidance of revision surgery [13]. In their series, 13 patients (68%) had at least one endoscopic sinus surgery with a mean elapsed time of 29 months between surgery and commencement of omalizumab therapy. The IgE levels in our study were not reduced in all patients post omalizumab therapy. We hypothesize that the reason for this is because omalizumab binds to IgE without changing its physiologic production. Hence, the absolute levels would therefore not be expected to change.

Although the administration of omalizumab in patients with refractory AFRS and moderate or severe asthma appears to be a promising salvage therapy, there are several limitations to its use. The cost of omalizumab is approximately CAD three thousand dollars per subcutaneous injection. Fortunately, in our study, the cost of omalizumab was fully subsidized by the Canadian Healthcare System for eligible patients. Omalizumab is also administered subcutaneously on a 2-weekly or monthly basis. For the first injection, patients have to be observed in the clinic for three hours, in the presence of a physician with training in advanced cardiac life support (ACLS) and nurses who are trained in basic cardiac life support (BCLS). A fully equipped resuscitation trolley has to be readily available in the clinic. These measures are necessary to ensure that in the event of an anaphylactic reaction, the patient can be managed appropriately. An anaphylactic reaction post omalizumab therapy has not been reported in the literature. In our series, one patient developed a significant side effect (dizziness and fever) upon administration of subcutaneous omalizumab therapy which resolved with close monitoring. Finally, the optimal duration

Fig. 5 – Comparison of immunoglobulin-Ε levels pre and post omalizumab therapy.
and dosage of omalizumab therapy for the treatment of CRSwNP or AFRS have yet to be determined.

There were a few limitations in our study. First, the number of patients involved in this study was small. As the cost of omalizumab therapy is high and its use in Canada is approved mainly in patients with moderate or severe asthma, recruitment of a large number of patients will be difficult. Second, there was no control group in our study. However, these were post surgery AFRS patients who have already failed medical treatments available in our center. Third, many of these patients were on multiple concurrent medical treatments (topical and systemic steroid, oral itraconazole or nasal irrigations) while on omalizumab therapy although the dependence on these medications was reduced after omalizumab therapy.

5. Conclusion

Omalizumab therapy is a viable option in the treatment of patients with refractory AFRS and moderate or severe asthma. A well-designed large prospective randomized controlled trial to determine the effects and optimal dosage and duration of omalizumab therapy in patients with AFRS will be necessary.

Acknowledgments

We would like to sincerely thank Rachelle Dar Santos, BSc, CCRP, for her support and guidance in the process of obtaining ethics approval.

REFERENCES